Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons
Abstract
Hydroxymethylglutaryl Co-enzyme A reductase inhibitors, also known as statins, are a class of anti-hyperlipidemic agents. These drugs have been employed vastly to reduce the morbidity and mortality of cardiovascular disorders. Soon after their introduction, benefits other than their primary actions were discovered. Along with these pleiotropic properties, a series of mainly favorable effects has been proposed in patients intended to undergo hematopoietic stem cell transplantation. These actions address some complications encountered by this special population such as graft-versus-host disease, efficacy of chemotherapy, infections, etc. This review presents the current evidence surrounding these issues.
Shimabukuro-Vornhagen A, Glossmann J, Liebig T, et al. The use of statins in hematopoietic stem cell transplantation. Curr Stem Cell Res Ther. 2009; 4(4):260-5.
Dhir S, Slatter M, Skinner R. Recent advances in the management of graft-versus-host disease. Arch Dis Child. 2014; 99(12): 1150-7. e-pub ahead of print 12 Jul 2014; doi: 10.1136/archdischild-2013-304832.
Lucena CM, Torres A, Rovira M, et al. Pulmonary complications in hematopoietic SCT: a prospective study. Bone Marrow Transplant. 2014; 49(10):1293-9. e-pub ahead of print 21 Jul 2014; doi: 10.1038/bmt.2014.151.
Servais S, Lengline E, Porcher R, et al. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(4):507-17.
Rotta M, Storer BE, Storb R, et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16(10):1463-6.
Yoon HK, Lim JY, Kim TJ, et al. Effects of pravastatin on murine chronic graft-versus-host disease. Transplantation. 2010 Oct 27; 90(8):853-60.
Rotta M, Storer BE, Storb RF, et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood. 2010 Feb 11; 115(6):1288-95.
Hamadani M, Gibson LF, Remick SC, et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol. 2013 Dec 10; 31(35):4416-23.
Boeckh M, Storer BE, Schubert MM, et al. The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation. Blood. 2013; 122 (21) 4548.
Hamadani M, Hade E, Benson DM, et al. The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant. 2008 Mar; 14(3):351-2.
Wong WW, Clendening JW, Martirosyan A, et al. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther. 2007 Jun; 6(6):1886-97.
Schmidmaier R, Baumann P, Bumeder I, et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol. 2007 Sep; 79(3):240-3.
van der Spek E, Bloem AC, Sinnige HA, et al. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica. 2007 Dec; 92(12):e130-1.
Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood. 2010 Aug 26; 116(8):1197-204.
Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007 Nov 1; 110(9):3463-71.
Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004 Sep 15; 104(6):1898-906.
Savani BN, Griffith ML, Jagasia S, et al. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011 Mar 17; 117(11):3002-9.
Kagoya Y, Seo S, Nannya Y, et al. Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant. 2012 Mar-Apr; 26(2):E168-75.
Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994 May 27; 57(10):1479-83.
Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation. 1998 Feb 15; 65(3):446-9.
Soveri I, Abedini S, Holdaas H, et al. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009 Nov-Dec; 23(6):914-20.
Taylor PJ, Kubler PA, Lynch SV, et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother. 2004 Feb; 38(2):205-8.
Blaser BW, Kim HT, Alyea EP, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005 Nov; 24(11):1736-40.
Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997 Sep 2; 96(5):1398-402.
Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003 Jan 7; 107(1):93-7.
Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant proc. 2004 Jun; 36(5):1539-41.
Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003 May 1; 167(9):1271-8.
Shirinsky IV, Zheltova OI, Solovyova NY, et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol. 2009 Jan-Feb; 38(1):23-7.
Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007 May; 34(5):964-8.
Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010 Jul; 16(7):848-54.
Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 May 15; 363(9421):1607-8.
Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010 Apr; 16(4):450-4.
Xu H, Yang YJ, Yang T, et al. Statins and stem cell modulation. Ageing Res Rev. 2013 Jan; 12(1):1-7.
Tousoulis D, Kaski JC, Antoniades C, et al. Beneficial effects of statin treatment after myocardial infarction: Is progenitor cell mobilization the missing link?. Int J Cardiol. 2008 Nov 28; 130(3):301-3.
Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol. 2008 Nov 28; 130(3):457-62.
Stravodimou A, Voutsadakis IA. Statin use and peripheral blood progenitor cells mobilization in patients with multiple myeloma. Clin Transl Oncol. 2014 Jan; 16(1):85-90.
Rossi G, Skert C, Morello E, et al. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. Hematol Oncol. 2015; 33(3):125-32. doi: 10.1002/hon.2148.
Teschke R, Frenzel C, Wolff A, et al. Rare statin hepatotoxicity: convincing evidence based on breakthrough case study. J Hepatol. 2012 Sep; 57(3):699-700.
Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005; 33(1):155-64.
Lucena MI, Garcia-Cortes M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008 Apr; 22(2):141-58.
Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012 Feb; 56(2):374-80.
Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010 May; 105(5):978-80.
Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):902-7; quiz 806.
Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004 May; 126(5):1287-92.
Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. 2002 Aug 20; 106(8):1024-8.
McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17; 97(8A):89C-94C.
Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007 Nov; 9(5):389-96.
Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: From clinical trials to everyday practice. Pharmacol Res. 2014; 88: 107-13 e-pub ahead of print 13 May 2014; doi: 10.1016/j.phrs.2014.04.012.
Kellick KA, Bottorff M, Toth PP. A clinician's guide to statin drug-drug interactions. J Clin Lipidol. 2014 May-Jun; 8(3 Suppl):S30-46.
Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone marrow transplant. 2005 Oct; 36(8):739-40.
Shahan JL, Panu LD, Hildebrandt GC. Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone. Int J Hematol. 2012 Dec; 96(6):818-9.
Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999 Dec; 84(3):413-28.
| Files | ||
| Issue | Vol 10, No 1 (2016) | |
| Section | Articles | |
| Keywords | ||
| Infection GvHD Statin Stem cell transplantation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
